EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
Phase 3negativeDuravyuNegative
AI Analysis
Summary
Eypoint Pharmaceuticals' Duravyu failed to meet its primary endpoint in a Phase III trial for an eye disease indication, causing the stock to plunge 67%.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Missed primary endpoint in Phase III trial
Importance:8/10
Sentiment:
-0.95
Phase 3 failureEye diseaseStock declineClinical trial
Related Companies
Read the original article
Published by yahoo_finance on August 18, 2026 2:33 PM